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1 This study was designed to determine whether clofilium exhibits antifibrillatory activity in a
pinacidil + hypoxia-induced model of ventricular fibrillation (VF) in Langendorff-perfused hearts.
2 Ten minutes after exposure to vehicle or clofilium (0.1, 1.0 and 10.0 JIM), hearts were exposed to
pinacidil (1.25 riM), then subjected to 12 min of hypoxia and reoxygenated. Onset to VF was recorded.
Additional groups of hearts were pretreated with UK-68,798 (1.0, 3.0 and 10.0 pLM), a delayed rectifier
channel blocker, and 5-hydroxydecanoate (1O iM), a known ATP-dependent K+ channel blocker, and
subjected to an identical protocol.
3 Clofilium decreased the incidence of VF in a concentration-dependent manner; 7/9 control hearts
developed VF vs 1/9 hearts (P = 0.007, Fisher's Exact) treated with 10.011M clofilium. In addition,
5-hydroxydecanoate protected hearts from VF, while UK-68,798 pretreatment did not.
4 In a separate group of hearts, electrically-induced VF was converted to sinus rhythm in 10/11 hearts
after clofilium was introduced as a bolus.
5 Clofilium is capable of preventing VF in the rabbit isolated heart in a concentration-dependent
manner. We have data to suggest that the ability of clofilium to attenuate the effects of pinacidil +
hypoxia in our model may include blockade of metabolically active K+ channels, i.e., KATP
(glibenclamide-sensitive) channel.
Keywords: Class III antiarrhythmic drugs; clofilium; UK-68,798; 5-hydroxydecanoate; ATP-dependent K+ channels; rabbit
isolated heart; chemical defibrillation; ventricular fibrillation
Introduction
In view of the inefficacy of Class I agents to prevent sudden
cardiac death, there is a renewed effort in the development of
antiarrhythmic drugs with selected cardiac electro-
physiological properties. Agents with demonstrated experi-
mental efficacy against ventricular arrhythmias include: UK-
68,798 (Black et al., 1991), CK3579 and sematilide (Chi et
al., 1990a), E-4031 (Lynch et al., 1989), ( ± )-sotalol (Lynch
et al., 1984), and amiodarone (Patterson et al., 1983). In each
of the examples cited, the incidence of ventricular fibrillation
(VF), or sudden cardiac death in the conscious dog, was
reduced significantly when compared to vehicle-treated con-
trols. Another promising investigational agent is WAY-
123,398, purported to prolong ventricular refractoriness and
increase the ventricular fibrillation threshold without affect-
ing impulse conduction (Spinelli et al., 1992).
The antiarrhythmic compound clofilium, is a bretylium
congener devoid of sympathomimetic or sympatholytic effects
(Steinberg & Molley, 1975; Steinberg et al., 1981; Lindstrom
et al., 1982). Clofilium has been shown to prolong the
effective refractory period or action potential duration in a
number of animal models (Steinberg & Molley, 1975;
Steinberg et al., 1981; Kowey et al., 1985; Wu et al., 1989; Li
et al., 1990) as well as to increase the refractory period in the
human ventricular myocardium without affecting conduction
time or haemodynamics (Greene et al., 1983). An additional
potential benefit of clofilium derives from its ability to
decrease the electrical energy requirement for ventricular
defibrillation (Kopia et al., 1985; Dorian et al., 1991). How-
ever, its reported mechanism of action varies with species and
model employed. For example, clofilium is capable of induc-
ing closed states in batrachotoxin-actived Na+ channels from
rabbit skeletal muscle (Nettleton et al., 1991). Others report a
decrease in outward potassium (delayed rectifier) current of
guinea-pig ventricular myocytes after clofilium treatment
(Snyders & Katzung, 1985), a finding repeated in ischaemic
Purkinje fibres of the dog (Gough et al., 1988). It has been
reported that the delayed rectifier, but not the inward rectifier
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current, is blocked by quaternary clofilium in guinea-pig
ventricular cells (Arena & Kass, 1988). Moreover, clofilium
and its tertiary homologue LY 97119 have been shown to
block the transient outward potassium current (Ito) in rat
ventricular myocytes (Castle, 1991). Most recently, clofilium
was shown to inhibit glibenclamide-sensitive K+ channels in
voltage-clamped Xenopus oocytes (Sakuta et al., 1993).
It is clear the clofilium may have the capacity to affect a
number of potassium channels in the normal or ischaemic
myocardium. To define further its antifibrillatory actions, we
studied clofilium in a Langendorff-perfused rabbit isolated
heart model in which KATP channels have been implicated in
the genesis of VF (Chi et al., 1993). The primary objective of
our study was to determine whether clofilium was capable of
antagonizing the effects of pinacidil, a known KATP channel
opener in ventricular myocardium, especially when applied in
the presence of hypoxia and an associated decrease in tissue
ATP content (Chi et al., 1993). The conditions for perfusion,
low extracellular K+, pinacidil and hypoxia, favoured the
induction of ventricular fibrillation through activation of the
KATp-dependent or glibenclamide-sensitive K+ channel (Chi
et al., 1993). We postulated that clofilium may owe its
antifibrillatory effect to the blockade of the metabolically
active KATP channel or glibenclamide-sensitive K+ channel.
We examined this hypothesis in the rabbit perfused isolated
heart.
Methods
Guidelines for animal research
The procedures followed in this study are in accordance with
the guidelines of the University of Michigan Committee on
the Use and Care of Animals. Veterinary care was provided
by the University of Michigan Unit for Laboratory Animal
Medicine. The University of Michigan is accredited by the
American Association of Accreditation of Laboratory
Animal Care. The animal care and use programme conforms
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to the standards in The Guide for the Care and Use of
Laboratory Animals, DHEW Publ. No. (NIH) 86-23.
Isolated heart preparation
New Zealand, white rabbits (1.8-2.0 kg) were rendered
unconscious by cervical dislocation. A median sternotomy
was performed immediately therafter and the heart removed.
The aorta was cannulated (Langendorff preparation) and
perfused with a buffer solution at a constant rate of
18-20 ml min-'. The time taken to complete the isolation of
the heart and initiate perfusion was less than 10 s. The
isolated heart was allowed to stabilize for approximately
20 min during which time, flow rate (Master Flex Roller
Pump, Cole Parmer, Chicago, IL, U.S.A.) was adjusted to
produce a coronary artery perfusion pressure of
50± 5 mmHg. Once a steady state had been established,
pump settings remained constant throughout the protocol.
The buffered perfusion medium (pH 7.4) was composed of
(in mM): NaCI 117, KCI 1.41, CaCl2 2.4, MgCl2 1.2,
NaHCO3 25, KH2PO4 1.1, glucose 5.0, L-glutamate (Na'
salt) 5.0 and sodium pyruvate 2.0. The final K+ concentra-
tion in the perfusate was 2.5 mM.
The perfusion medium was passed through an 'artificial
lung' that consisted of 6 m of medical grade gas permeable
tubing (Silastic, Dow Corning Corp, Midland, MI, U.S.A.)
placed in a double-walled, water-heated chamber. Changing
the oxygen mixture in the lung chamber caused the perfusion
medium to equilibrate with the introduced gas mixture within
60s.
During normoxia, the chamber was gassed continuously
with 95% 02/5% C02. Hypoxia was produced by gassing the
chamber with 95% N2/5% CO2. The temperature of the
perfusion medium and isolated heart were maintained at
370C using a temperature controlled circulating water bath.
The hearts were paced electrically from the right atrium at a
frequency of 20-30% above the intrinsic sinus rate. Electri-
cal pacing was maintained for the duration of each protocol.
A latex balloon was advanced into the left ventricle
through an incision in the left atrial appendage and con-
nected via a rigid cannula to a pressure transducer positioned
at the level of the heart. The intraventricular balloon was
expanded with distilled water to establish a ventricular end-
diastolic pressure of 5 mmHg. Continuous measurement of
left ventricular isovolumic developed pressure and end-
diastolic pressure were made with the intraventricular bal-
loon. A polyethylene cannula was placed in the left ventricle
to vent the chamber of fluid entering the left ventricle via the
Thebesian vessels. A thermistor probe (Tele-thermometer,
Yellow Springs Instrument Co., Yellow Springs, OH, U.S.A.)
was inserted in the left ventricle to monitor the temperature
of the heart. A pressure transducer was attached to a side
arm of the aortic cannula and was zeroed at the level of the
heart. The rate of coronary artery flow was maintained con-
stant by the roller pump. Therefore, changes in perfusion
pressure in the aortic cannula reflected changes in coronary
artery resistance.
Oxygen tension (Po2) of the perfusion buffer was
monitored continuously by an in-line Clark type oxygen
electrode (Instech dual oxygen electrode amplifier model 203,
Instech Laboratories, Plymouth Meeting, PA, U.S.A.) placed
immediately proximal to the aortic cannula. The electrogram
was recorded from leads placed on the aorta and at the
cardiac apex.
The following parameters were recorded with a Model 7
Grass Polygraph (Grass Instrument Co. Quincy, MA,
U.S.A.): electrogram, monophasic action potential, coronary
perfusion pressure, left ventricular pressure and its first
derivative ± dP/dt.
Experimental protocol
Hearts were randomized by blind selection of preassigned
treatments. Ten experimental groups, consisting of Langen-
dorff perfused hearts were used in this study: Group I:
Vehicle + pinacidil (1.25 gEM) + hypoxia + reoxygenation (n =
9); Group II: clofilium (0.1 AIM) + pinacidil (1.25 jM) +
hypoxia + reoxygenation (n = 7); Group III: clofilium (1.0 jM)
+ pinacidil (1.25 EM) + hypoxia + reoxygenation (n = 7); Group
IV: clofilium (10.0 AM) + pinacidil (1.25 gM) + hypoxia + re-
oxygenation (n = 9); Group V: electrophysiological studies
(n = 8); Group VI: electrically induced ventricular fibrillation,
treatment with clofilium (n = 11); Group VII: UK-68,798
(1.0 jM) + pinacidil (1.25 gM) + hypoxia + reoxygenation (n =
5); Group VIII: UK-68,798 (3.0 jM) + pinacidil (1.25 AM)
+ hypoxia + reoxygenation (n = 4); Group IX: UK-68,798
(10.0 AM) + pinacidil (1.25 jIM) + hypoxia + reoxygenation (n =
5); Group X: 5-hydroxydecanoate (10.0 AM) + pinacidil (1.25
gm) + hypoxia + reoxygenation (n = 9).
A drug-free equilibration period of 20 min elapsed before
the start of each protocol (Figure 1). In groups I-IV, clofilium
or drug-free buffer, perfused the hearts for 10 min. In groups
VII-X either UK-68,798 or 5-hydroxydecanoate was added to
the buffer and perfused the hearts for 10 min. Pinacidil was
added to the buffer to achieve a final concentration of 1.25 jM.
Five minutes after pinacidil was added to the perfusion
medium, global hypoxic perfusion was initiated by changing
the gas mixture in the 'artificial lung' to 95% N2 5% Co2. The
state of global hypoxic perfusion was maintained for 12 min
(hypoxic period). Normoxic perfusion was re-established by
returning the gas mixture in the 'artificial lung' to 95% 02, 5%
CO2 (reoxygenation) for the remaining 40 min of the experi-
mental protocol. The period of time to onset of spontaneous,
sustained ventricular fibrillation (30 s minimum) was recorded.
Groups I-IV and VII-X were studied under conditions of a
reduced potassium concentration (2.5 mM) in the perfusion
medium. Under these conditions, during global hypoxic per-
fusion, myocardial ATP content decreases approximately 50%.
We have shown in the past that under conditions of 2.5 mM
K+ and reduced ATP, the heart becomes susceptible to the
development of ventricular fibrillation in the presence of
pinacidil (Chi et al., 1993).
Electrophysiological effects of clofilium
In Group V hearts, a miniature bipolar plunge electrode
(INAPRES, Norwich, NY, U.S.A.) was sutured over the right
ventricular outflow tract (RVOT) for delivery of the S2 vent-
ricular stimulus from a Grass S8800 square wave stimulator
and stimulus isolation unit (SIU5; Grass Instrument Co.,
Quincy, MA, U.S.A.). The S2 stimulus duration was 4 ms and
was triggered 250 ms after the R wave of the ECG. The
threshold current was defined as the minimum current required
to elicit a propagated ventricular impulse. To determine
effective refractory period (ERP), stimulation (S2) to the
RVOT (at 1.5 times threshold current) was initiated at a
250 ms delay. The S2 delay stimulation was decreased
repeatedly by 10 ms until the refractory period was reached.
The refractory period determined in the region of the RVOT is
defined as the longest R-wave stimulus interval that fails to
elicit a propagated ventricular complex.
Clofilium 0.1, 1.0, 10.0 gM
Pinacidil 1.25 gM
Hypoxia Reoxygenation
-15 -5 0 12 52
Time (min)
Figure 1 Experimental protocol for Groups I-IV and VII-X; hat-
ched areas, 95% 02/5% C02; open areas, 95% N2/5% CO2.
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Determination of the ventricular effective refractory period
under conditions of low K+ (2.5 mM) invariably resulted in the
induction of ventricular fibrillation. Therefore, Group IV
hearts were perfused with perfusion medium containing a
potassium concentration of 5.1 mM. Refractory periods were
determined at 5, 15 and 30 min after clofilium was added to
the perfusion medium.
A Ag-AgCl electrode was used to record the endocardial
monophasic action potential duration. Action potential dura-
tions (APD) at 90% repolarization were determined at
baseline, 10 min after addition of clofilium, and 5 min after
pinacidil plus clofilium in groups II-IV.
Group VI hearts received a train of stimuli delivered to the
region of the RVOT (S2, S3, S4-instead of a single impulse)
until ventricular fibrillation occurred. After 30 s of sustained
ventricular fibrillation, a volume of drug diluent (perfusion
medium) was administered immediately proximal to the can-
nulated aorta. Time for injection to reversion of normal sinus
rhythm was recorded. If 30 s had elapsed and reversion was
not evident, clofilium (0.35 or 0.6 ml of 10.0 mM), dissolved in
perfusion medium, was administered rapidly, and time to
return of normal rhythm was recorded.
Drugs
Pinacidil and clofilium were gifts from the Eli Lilly Co.
(Indianapolis, IN, U.S.A.). A stock solution of pinacidil was
prepared daily, by dissolving the drug in acidified perfusate
(pH 2.0-2.5). The stock solution was added to the perfusion
buffer to yield a final concentration of 1.25 gtM. Clofilium was
dissolved in the perfusate buffer and prepared just before use
in each experiment. UK-68,798 (dofetilide) was a gift from
Pfizer Central Research (Sandwich, U.K.) and 5-hydroxy-
decanoate was a gift from Parke-Davis (Ann Arbor, MI,
U.S.A.). Analytical grade chemicals used for preparation of
the buffer solution were obtained from commercial sources.
Statistical analysis
The data are expressed as mean ± s.e.mean. The difference
between groups (fibrillation occurrence) was analysed by
Fisher's Exact test. A one-way ANOVA was used for com-
parisons between groups (factorial) at specific time points, as
well as within groups (repeated measures). Differences were
considered significant at P <0.05.
Results
Antifibrillatory effects of clofilium
The antifibrillatory effect of clofilium was examined in a
Langendorff-perfused rabbit isolated heart model in which
ventricular fibrillation was induced by the combined introduc-
tion of pinacidil (1.25 IAM) to the perfusion medium with the
subsequent induction of global hypoxia for 12 min followed by
reoxygenation for 40 min. Exposure of the heart to pinacidil
(1.25 JtM) during normoxic perfusion, did not result in the
development of cardiac arrhythmias. However, when pinacidil-
treated hearts were subjected to 12 min of hypoxia followed by
reoxygenation, there was a 78% (7 of 9 hearts) incidence of
ventricular fibrillation in the control group (Group I). Most of
the hearts in Group I developed ventricular fibrillation during
hypoxia or within the first 20 min of reoxygenation (Figure 2).
Clofilium pretreatment was associated with a concentration-
related suppression in the incidence of ventricular fibrillation.
At a concentration of 10.0 fLM, 1 of 9 (11%) hearts developed
ventricular fibrillation during the period of reoxygenation
(P <0.05 vs vehicle-treated hearts; Figure 2). Clofilium con-
centrations of 0.1 and 1.0 gM did not confer a significant
protective effect against the induction of ventricular fibrillation
upon exposure to the combined effects of pinacidil and
hypoxia/reoxygenation.
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Figure 2 Incidence of ventricular fibrillation in the presence of
vehicle or clofilium. Each symbol represents an individual isolated
heart. *P<0.05 vs vehicle, Fisher's exact test.
Effects of UK-68,798 and 5-hydroxydecanoate on
ventricular fibrillation
Groups VII-IX were added to our study to determine if
another putative Class III antiarrhythmic agent, devoid of
ATP-dependent/glibenclamide-sensitive K+ channel blocking
activity, was able to prevent the induction of ventricular fibril-
lation by exposing the perfused heart to the combined effects
of pinacidil and hypoxia. The selective inhibitor of the rapid
component of the delayed rectifier channel, UK-68,798 was
used to test this hypothesis. Finally, Group X was included to
examine a specific ATP-dependent/glibenclamide-sensitive K+
channel blocker, 5-hydroxydecanoate, in the isolated heart
model of ventricular fibrillation.
UK-68,798 pretreatment was not associated with a
concentration-related suppression in the incidence of ven-
tricular fibrillation. At a concentration of 10.0 JM, 3 of 5
(60%) hearts developed ventricular fibrillation during the
period of reoxygenation (Figure 3). UK-68,798 concentrations
of 1.O0M (80% VF) and 3.011M (100% VF) did not confer a
significant protective effect against the induction of ventricular
fibrillation upon exposure to the combined effects of pinacidil
and hypoxia-reoxygenation. However, at a concentration of
10tiM, 5-hydroxydecanoate, reduced the incidence of ven-
tricular fibrillation to 2 of 9 (22%) hearts during the period of
reoxygenation (P<0.05 vs vehicle treated hearts).
Effects of clofilium on cardiac function
Coronary perfusion pressure (Table I) did not differ between
Groups I-IV at baseline. The highest concentration of
Non-
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Hypoxia
Figure 3 Incidence of ventricular fibrillation in the presence of
UK-68,798 and 5-hydroxydecanoate (5-HD). Each symbol represents
an individual isolated heart. *P<0.05 vs vehicle, Fisher's Exact test.
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52 ± 3 (9)
37 ± 2 (9)'
31 ± 4 (7)'
40 ± 4 (7)'
48 ± 3 (5)
0.1 JM
52±1 (7)
57 ± 2 (7)'
45 ± 2 (7)ab
38 ± 4 (7)'
45 ± 3 (6)'
57 ± 9 (3)
1.0 pM
61±4 (7)
66 ± 6 (7)'
50 ± 4 (7)ab
42 ± 4 (7)a
55 ± 6 (7)
59 ± 6 (5)
82 ± 18 (4)
10.0OfM
58 ± 3(9)
50 ± 2 (9)-C
48 ± 2 (9)ab
38 ± 3 (8)'
53 ± 4 (8)
55 ± 4 (8)
75 ± 6 (8)a
Data are expressed as mean ± s.e.mean, n in parentheses.
'P< 0.05 vs. corresponding baseline; bP< 0.05 vs. respective clofilium (0 min); CP< 0.05 vs 1.0 gM clofilium
clofilium (10.0 JAM) produced a reduction in coronary perfusion
pressure from baseline, 58 ± 3 mmHg to 50 ± 2 mmHg after
10 min of exposure (P <0.05). More striking was the coronary
perfusion pressure (CPP) response upon the subsequent
administration of pinacidil (1.25 JAM). For hearts treated with
0.1 and 1.0 JM clofilium, CPP decreased in the presence of
pinacidil. In contrast, hearts treated with 10.0 JM clofilium
exhibited a modest reduction of CPP. Clearly, at a concentra-
tion of 10.0 JAM clofilium attenuates the vasodilator effects of
pinacidil. Hypoxia further decreased CPP in each group and
there were no differences in coronary artery perfusion pressure
among groups during hypoxia or reoxygenation.
Clofilium produced minimal effects upon myocardial con-
tractile performance when added to the perfusion medium
(10.0 JAM) compared to the control group of hearts. In hearts
exposed to clofilium followed by pinacidil (1.25 JM), + IP/dt
was 475 ± 6 mmHg s-', compared to 470 ± 9 mmHg .s-'
before pinacidil treatment. Vehicle-treated hearts typically
exhibit a 10% reduction in + RP/dt upon the addition of
pinacidil (1.25 JiM), clofilium attenuated this response. During
hypoxia, (t = 12 min) + IP/dt was 355 ± 14 mmHg s-' in the
clofilium-treated group. Lower concentrations of clofilium
failed to show significant haemodynamic changes compared to
vehicle-treated hearts throughout the experimental protocol.
Electrophysiological effects of clofilium
As shown in Table 2, a group of hearts was used for the
characterization of the ventricular effective refractory period
(ERP) determinations in the absence and presence of
cumulative concentrations of clofilium (0.3, 1.0 and 3.0 JiM). In
the presence of the lowest concentration of clofilium (0.3 J1M),
ERP increased 17 ± 5% above baseline after 30 min of
exposure (P <0.05). At a concentration of 1.0 JM, clofilium
progressively increased ERP 25 ± 9% above baseline after
Table 2 Ventricular effective refractory p
paced rabbit isolated hearts in the prese
concentrations of clofilium




156 ± 13 173 ± 16
- 177 ± 15
- 190±15 24




15 min 30 min
75± 17a 170±9a
84± 15 189±9a
03 ± 13' 213± 16'
ive to predrug
30 min of exposure to the drug in the perfusion medium. An
additional prolongation to 213 ± 16 ms was found after 30 min
of exposure to 3.0 JM clofilium (P<0.05 vs baseline). The
total increase in ERP was 37 ± 18% compared to baseline
values. Stepwise increases above 3.0 JM clofilium decreased
atrioventricular conduction velocity and interfered with the
ability to maintain atrial pacing. Therefore the elect-
rophysiological effects of clofilium at concentrations greater
than 3.0 JM were not studied.
Action potential durations (APD) at 90% repolarization
were determined at baseline, 10 min after addition of clofilium,
and 5 min after pinacidil plus clofilium in groups II-IV. Table
3 summarizes the results. The changes in APD were not as
profound in our preparation as were the changes in measured
refractory period after clofilium exposure. An important result
was obtained in this portion of the study. While we measured
only slight increases in APD after clofilium alone, there was a
significant change in APD after pinacidil had been
administered. After the lowest 2 concentrations of clofilium
had been administed (0.1 and 1.0 JAM), pinacidil reduced APD
(P<0.05 vs corresponding baseline). In the presence of
10.0 JM clofilium, there was no reduction in APD compared to
baseline. These findings indicate that the prevention of APD
shortening by 10.0 JAM clofilium may contribute to its
antifibrillatory action.
Chemical defibrillatory effects of clofilium
Hearts in Group VI were used to explore the ability of
clofilium to achieve chemical defibrillation in the isolated per-
fused heart. Ventricular fibrillation was induced by direct cur-
rent pulses applied to the RVOT of the isolated heart while
coronary flow was maintained constant. Ventricular fibrillation
was permitted to persist for a period of 30 s to ensure the
presence of a persistent state of fibrillation after which a
volume of vehicle buffer was administered just proximal to the
aorta. Repeated administration of the drug diluent did not
influence the fibrillation status of the isolated heart. Isolated
perfused hearts, while in ventricular fibrillation, were given a
single dose of clofilium (0.35 or 0.60 ml of a 10 mM solution)
rapidly, immediately above the aorta. Conversion of the
electrically-induced VF to normal sinus rhythm occurred in 10
of 11 hearts (Figure 4). The mean time to conversion was
14 ± 2 s in 5/5 hearts (P<0.05 vs vehicle), using 0.35 ml of
10.0 mM clofilium. Time to conversion after 0.60 ml of
10.0 mM clofilium was 42 ± 13 s in 5/6 hearts (P<0.05 vs
vehicle). The longer time to conversion in the latter group was
related to sinus arrest associated with exposure to 0.6 ml of
Table 3 Action potential duration (ms) on paced rabbit isolated hearts during baseline, and in the presence of clofilium and pinacidil




123 8' (-9+ 5)
134 8' (-4 5)
142 ± 11 (+4± 2b)
Data are mean ± s.e.mean at 90% repolarization (ms). Values in parentheses represent % change from baseline. ap <0.05 vs
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Baseline electrogram
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60 s post Clofilium bolus
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Figure 4 (a) Electrogram (left), and corresponding left ventricular pressure (right); under baseline conditions. (b) Electrogram after
60 s of sustained ventricular fibrillation (L) and left ventricular function (R). (c) Electrogram after induction of clofilium bolus
(0.6 ml of 10 mM) to the heart (L) and left ventricular function (R). (d) Electrogram 30 s post administration of clofilium (L) and
left ventricular function (R). (e) Electrogram 60 s post administration of clofilium (L) and left ventricular function (R).
10 mM clofilium. The administration of a non-drug containing
volume of perfusion buffer was used as a vehicle control.
Introduction of the placebo buffer never resulted in the conver-
sion of ventricular fibrillation to sinus rhythm.
Discussion and conclusions
The inefficacy of many Class I agents for the prevention of
sudden cardiac death has prompted a renewed effort in the
development of antiarrhythmic drugs. Class III antiarrhyth-
mic therapy targeting lethal arrhythmias is receiving much
attention. Several Class III agents in various stages of
development have been reported to be efficacious in animal
models characterized by the development of ventricular fibril-
lation (Lynch et al., 1984; Chi et al., 1990a; Black et al.,
1991). It is novel however to find an agent that possesses not
only an antiarrhythmic/antifibrillatory capacity, but a
defibrillatory capacity. Reports in the past have ascribed this
effect to bretylium (Bacaner, 1968; Sanna & Arcidiacono,
1973), but the effects of bretylium on the sympathetic ner-
vous system, i.e., release of catecholamines from sympathetic
nerve terminals (Boura & Green, 1959) and side effects of
hypotension contributed to its lack of widespread use.
Clofilium, another quaternary antiarrhythmic agent has been
shown to prolong the effective refractory period or action
potential duration in animal models (Steinberg & Molloy,
1975; Steinberg et al., 1981; Kowey et al., 1985; Wu et al.,
1989; Li et al., 1990) as well as increase the refractory period
in man without affecting conduction time or haemodynamics
(Greene et al., 1983). The role of clofilium as an
antifibrillatory agent has been shown to be beneficial by
lowering defibrillation requirements (Kopia et al., 1985;
Dorian et al., 1991). To date, there has not been a report
that systematically describes the chemical defibrillatory
ability of clofilium. We have evidence that clofilium, which
up to now has been considered to be a ItO/IK (Arena & Kass,
1988; Castle, 1991) channel blocker is not only efficacious as
an antifibrillatory agent, but as a defibrillatory agent as well.
While it is generally understood that ATP-dependent
potassium channels (glibenclamide-sensitive channels) are
closed under normal conditions (Noma, 1983), blockade of
channels that are closed would be expected to produce few
measurable effects. Under normal conditions, the rabbit
isolated heart treated with graded concentrations of clofilium
responds by a progressive increase in the ventricular effective
refractory period (Table 2). We observed slight increases in
the duration of the monophasic action potential after
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clofilium administration (Table 3). If the mechanism of
action of clofilium were KATP channel blockade, we would
expect to find very little change in either measure. This was
not the case, which implies that clofilium does not block the
ATP dependent K+ channel under normal conditions during
which the intracellular ATP concentration is not perturbed.
Blockade of delayed rectifier current by clofilium in ischaemic
Purkinje fibres has been reported by several investigators
(Gough et al., 1988; Reeve, 1992). In the present study,
clofilium produced a dose-dependent increase in the effective
refractory period, whereas changes in the monophasic action
potential duration (90% repolarization) failed to reach statis-
tical significance after 10 min of exposure. This is not surpris-
ing since it has been reported that clofilium causes substantial
prolongation of action potential duration in the Purkinje
fibre, but the duration was unchanged in the ventricular
muscle cell (Carlsson et al., 1992).
Addition of pinacidil before induction of hypoxia
unmasked effects of clofilium not associated with blockade of
channels associated with the transient outward (Ito) or
delayed rectifier currents. In the presence of lower concen-
trations of clofilium (0.1 and 1.0 pM), pinacidil exposure
produced a reduction in the monophasic action potential
duration. The highest dose of clofilium (10.0tiM), however,
prevented the pinacidil-induced reduction in the monophasic
action potential duration. Therefore the functional data
implicate clofilium in the blockade of ATP-dependent potas-
sium channels in the presence of the KATP channel opener,
pinacidil (Arena & Kass, 1989; Martin & Chinn, 1990). In
support of our functional data is a recent report in which
clofilium was capable of inhibiting glibenclamide-sensitive
K+ channels in voltage-clamped Xenopus oocytes (Sakuta et
al., 1993). However, we cannot exclude the possibility of a
functional antagonism by clofilium. The action potential
duration shortening by pinacidil may be counteracted by
blockade by clofilium of transient outward and/or delayed
rectifier currents, the net result being little change in the
duration of the monophasic action potential.
Membrane channel activity becomes more complex as the
biochemical cascade of events associated with hypoxia ensues.
In our experimental model, control hearts subjected to
hypoxia in the absence of pinacidil had a 20% incidence of
ventricular fibrillation as compared to the significant increase
when pinacidil was present in the perfusion medium. The
results indicate that opening of the KATP channel by pinacidil,
together with a previous hypoxic insult and decrease in intra-
cellular ATP content, is pivotal in the promotion of ventri-
cular fibrillation (Chi et al., 1993). Clofilium (10.0IM) con-
sistently prevented the development of ventricular fibrillation
under the same experimental conditions that otherwise pro-
ved to be arrhythmogenic. Moreover, administration of two
additional agents possessing known pharmacological activity
on myocardial potassium channels add support to our
findings. UK-68,798 which has been shown to block selec-
tively the delayed rectifier current (Gwilt et al., 1989; Ras-
mussen et al., 1992; Carmeliet, 1992) was not effective in
reducing the incidence of ventricular fibrillation in response
to pinacidil plus hypoxia. In contrast, the administration of
5-hydroxydecanoate, a well characterized inhibitor of the
ATP-dependent K+ channel (Niho et al., 1987; Notsu et al.,
1992; Notsuto et al., 1992) was equally as effective as
clofilium in preventing the development of ventricular fibril-
lation.
It is reasonable to believe that clofilium is able to block
not only the transient outward and/or the delayed rectifier
potassium currents, but the metabolically active ATP-
dependent potassium channel under conditions of decreased
intracellular ATP that would promote its opening. In the
present experimental model, pinacidil administration in the
presence of a reduced intracellular ATP content, would be
expected to facilitate opening of the ATP-dependent potas-
sium channel. The increase in the outward potassium current
via the ATP-dependent potassium channel most likely
accounts for the initiation of ventricular fibrillation; an event
that can be prevented by glibenclamide (Chi et al., 1993), and
5-hydroxydecanoate. It follows that clofilium may owe part
or all of its antifibrillatory action to the prevention of action
potential shortening via blockade of ATP-dependent K+
channels. The prevention of ventricular fibrillation in the
present experimental model may be dependent upon a very
specific electrophysiological derangement initiated by opening
of the ATP-dependent potassium of glibenclamide-sensitive
channel. This specific action of clofilium may not occur
under conditions in which the initiation of ventricular fibrilla-
tion is not associated with opening of the ATP-dependent
potassium channel. Hypoxia-induced decrease in myocardial
ATP content increases the responsiveness of the ATP-
dependent K+ channel to the opening effects of pinacidil.
The experimental model, therefore, utilizes the vulnerability
of the heart under a specific set of conditions to explore the
role of the ATP-dependent K+ channel in the genesis of
ventricular fibrillation. Using this approach, it becomes pos-
sible to identify those pharmacological interventions capable
of preventing ventricular fibrillation arising from opening of
the ATP-dependent potassium channel. Clofilium, in addition
to its other potential effects on myocardial membrane potas-
sium channels, appears to have a salutary effect similar to
that of glibenclamide and 5-hydroxydecanoate, and radically
different from that of dofetilide (UK68,798) in terms of
preventing ventricular fibrillation. These observations sup-
port the concept that clofilium has the potential to modulate
the ATP-dependent potassium channel and to prevent those
electrophysiological changes leading to ventricular fibrillation
associated with decreases in myocardial tissue ATP content.
It is noteworthy that clofilium is capable of reverting elect-
rically induced sustained ventricular fibrillation to sinus
rhythm. This group of hearts was an addendum to our
primary study after we had noted that 4/9 hearts in the
10.0yM clofilium group reverted to sinus rhythm after tran-
sient episodes of spontaneous ventricular flutter during the
40 min reperfusion period, a phenomenon that has not been
observed in vehicle-treated rabbit hearts. A bolus of clofilium
(0.35 ml of 10 mM) slowed the rate of fibrillation, until the
heart resumed normal sino-atrioventricular conduction
within 14 ± 2 s. This event was observed in 5 isolated hearts.
A larger quantity of administered clofilium (n = 5, 0.6 ml of
10 mM) to the fibrillating heart, not only slowed the fre-
quency of fibrillatory waves, but elicited sinoatrial arrest.
Since coronary perfusion was maintained constant in our
preparation, and oxygen delivery uncompromised, the heart
was capable of resuming normal sinus rhythm in 42 ± 16 s.
The ability of clofilium to antagonize the coronary
vasodilator action of pinacidil should not be overlooked.
Before induction of hypoxia, pinacidil alone produced
vasodilatation and a negative inotropic effect on the rabbit
isolated perfused heart. The first derivative of left ventricular
pressure, + RP/dt is reduced approximately 10% within
5 min after pinacidil was added to the perfusion medium.
The presence of clofilium in the perfusate attenuated this
effect (see Table 1). It is well known that pinacidil is capable
of specific KATP channel activation (Arena & Kass, 1989),
while others report a profibrillatory effect of pinacidil (Chi et
al., 1990a, 1993). This evidence suggests that pinacidil will
promote ventricular fibrillation given the proper substrate or
altered physiological conditions. Clofilium prevents these res-
ponses, thereby leading us to suggest that clofilium (10.0 jiM)
may, in part, block the metabolically activated ATP-
dependent potassium channel. This conclusion is supported
by the observation that UK-68,798 (specific delayed rectifier
current antagonist) was not effective, while 5-hydroxy-
decanoate (specific ATP-dependent K+ current antagonist)
was effective in attenuating the development of ventricular
fibrillation. It may be that clofilium has been overlooked as a
potentially efficacious antifibrillatory agent.
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